Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial targets specific cancer weakness

NCT ID NCT06360588

Summary

This study is testing whether the drug copanlisib can help treat advanced cancers that have lost a specific protein called PTEN. The drug aims to block signals that cancer cells need to grow. The trial includes about 22 patients with various solid tumors that have not responded to standard treatments, to see if their tumors shrink or stop progressing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • ECOG-ACRIN Cancer Research Group

    Philadelphia, Pennsylvania, 19103, United States

Conditions

Explore the condition pages connected to this study.